Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fangbianfang plus standardized Western medicine for elderly patients with mild to moderate COVID-19
ChiCTR2300071747Phase 4Recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Jan 2023
- Countries
- 1
01
Overview
Phase 4, open-label trial of fangbianfang in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoint: Clinical recovery within 28 days. Started Jan 2023; status: recruiting.
02
Drugs
fangbianfang
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ChiCTR2300071747.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300071747.